NYSE - Delayed Quote USD

AbbVie Inc. (ABBV)

169.42

+0.85

(+0.50%)

At close: June 7 at 4:00 PM EDT

169.41

-0.01

(-0.01%)

After hours: June 7 at 7:52 PM EDT

Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval

Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.

Zacks 2 days ago

ABBV
+0.50%
LLY
+1.52%
GOOG
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal

Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.

Zacks 2 days ago

ABBV
+0.50%
AZN

PFE
-0.76%
Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO

After 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed disappointing obesity drug data and AbbVie got some good trial news.

BioPharma Dive 2 days ago

002722.SZ

ABBV
+0.50%
AbbVie reports positive Phase II ovarian cancer trial data

In the trial, treatment with mirvetuximab soravtansine offered a 51.9% objective response rate in ovarian cancer patients.

Clinical Trials Arena 2 days ago

ABBV
+0.50%
Is AbbVie Inc. (NYSE:ABBV) the Most Undervalued Dividend Aristocrat Stock According to Analysts?

We recently compiled the list of 25 Best Dividend Aristocrats Stocks According to Analysts. Since AbbVie Inc. (NYSE:ABBV) is part of our list, we have analyzed the stock in detail. The age-old debate of investing in dividend growth or high-yield stocks continues to reappear within the dividend investing realm. Between these two, dividend growth is currently […]

Insider Monkey 3 days ago

ABBV
+0.50%
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug

The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.

Zacks 3 days ago

ABBV
+0.50%
ARQT

JNJ
+0.45%
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (ELAHERE®) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The study met its primary endpoint with an objective response rate (ORR) of 51.9% (95%CI 40.4 – 63.3%).

PR Newswire 3 days ago

ABBV
+0.50%
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the makers of BOTOX® Cosmetic (onabotulinumtoxinA), is celebrating 25 years of SkinMedica®. To mark this milestone anniversary, Allē Members who purchase SkinMedica® products at a participating Allē Health Care Provider or SkinMedica.com from June 1 to June 25, 2024 can earn double points* and enter for a chance to win $5,000.**

PR Newswire 3 days ago

ABBV
+0.50%
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers

AbbVie (NYSE: ABBV) today launched the AbbVie Migraine Career Catalyst AwardTM, a first-of-its-kind contest designed to support the career, workplace, and professional development aspirations of people living with migraine. With more than 113 million workdays lost in the U.S. each year to the disease and its symptoms, migraine can have a major impact in the workplace.1 Twenty contest entrants will win up to $2,500 that they can decide to use toward career support, including career counseling, pr

PR Newswire 3 days ago

ABBV
+0.50%
AbbVie treats first subject in Phase III multiple myeloma drug trial

Progression-free survival and overall response rate are the trial's dual primary endpoints.

Clinical Trials Arena 3 days ago

ABBV
+0.50%
2 High-Yield Dividend Stocks to Buy Right Now

These two high-yield dividend stocks are top buys right now.

Motley Fool 4 days ago

ABBV
+0.50%
PFE
-0.76%
^GSPC
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie (NYSE: ABBV) today announced that the first patient has been treated with investigational ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a distinctive B-cell maturation antigen (BCMA) and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA-avidity and a low-affinity CD3 binding domain.1 ABBV-383 is being evaluated in a Phase 3, multicenter, randomized, open-label study compared with standard available therapies in patients with r/r M

PR Newswire 4 days ago

ABBV
+0.50%
Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks

A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study.

BioPharma Dive 4 days ago

ABBV
+0.50%
CYTK

LLY
+1.52%
AbbVie’s RINVOQ now indicated for paediatric arthritis in US

RINVOQ LQ oral solution is also available for paediatric polyarticular juvenile idiopathic arthritis and psoriatic arthritis patients.

Pharmaceutical Technology 4 days ago

ABBV
+0.50%
3 Dividend Stocks You May Want To Double Down On

Sometimes, misunderstood stocks benefit investors. Savvy investors can capitalize when a stock is incorrectly perceived as weak during a recession. Several high-yield dividend stocks currently fall into this category. Here, we’ll look at three worth ...

Benzinga 5 days ago

ABBV
+0.50%
CVX
+0.10%
PFE
-0.76%
Top Stocks to Buy in June

Here are a few high-quality stocks trading at intriguing valuations.

Motley Fool 5 days ago

ABBV
+0.50%
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis

AbbVie (NYSE: ABBV) today announced that RINVOQ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. Additionally, a new weight-based oral solution, RINVOQ® LQ (upadacitinib), is now available as an option for these pediatric popu

PR Newswire 5 days ago

ABBV
+0.50%
Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the debut of Refer a Friend, a new offering from Allē, the Allergan Aesthetics Loyalty Rewards Program. Now, Allē Members can invite their friends and family to join and both parties can receive savings on Allergan Aesthetics products or treatments from brands like BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® Collection of Fillers, SKINVIVE by JUVÉDERM®, CoolSculpting®, SkinMedica®, and DiamondGlow®.

PR Newswire 5 days ago

ABBV
+0.50%
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

In the most recent trading session, AbbVie (ABBV) closed at $160.19, indicating a -0.65% shift from the previous trading day.

Zacks 6 days ago

ABBV
+0.50%
^GSPC
AbbVie (ABBV) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Zacks 6 days ago

ABBV
+0.50%

Performance Overview

Return	ABBV	S&P 500
YTD	+11.40%	+12.10%
1-Year	+30.18%	+24.82%
3-Year	+69.97%	+26.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AbbVie Inc. (ABBV)

Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval

AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal

Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO

AbbVie reports positive Phase II ovarian cancer trial data

Is AbbVie Inc. (NYSE:ABBV) the Most Undervalued Dividend Aristocrat Stock According to Analysts?

AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug

AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer

SkinMedica® Celebrates 25 Years of Empowering Radiant Skin

AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers

AbbVie treats first subject in Phase III multiple myeloma drug trial

2 High-Yield Dividend Stocks to Buy Right Now

AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks

AbbVie’s RINVOQ now indicated for paediatric arthritis in US

3 Dividend Stocks You May Want To Double Down On

Top Stocks to Buy in June

RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis

Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) Could Be a Great Choice

Performance Overview